|
109 documents found matching dt:outline.
|
|
of 11
Prev
Next
|
|
|
|
Showing 1-10 of 109 documents
|
1.
Emerging Uses - Psychiatry
|
Document Date:
|
00000000
|
|
Search Terms in Context:
|
Emerging Uses - Psychiatry
CME Activities
Direct Mail (2nd wave) - Aug 1997
U.S. Psychiatric & Mental Health Congress Symposium - Nov 1997
- bipolar & social phobia symposium; symposium supplement to be included with Psychiatric Times
Psychiatry Dinner Programs - 1Q98
Market Research
Depakote currently has over 80% of use among AEDs for bipolar
rn
disorders. In contrast, Neurontin use is 1% among AEDs.
chi
(PDDA MAT 4/97)
1\) co
pgNbr=1
Emerging Uses - Neuropathic Pain
Clinical Studies
Diabetic Neuropathy (945-210)
- study completed: Apr 1997
- preliminary results: Neurontin was statistically and clinically superior to placebo
- post-investigators meeting: Sept 5 - 7, 1997
- manuscript: Sept 1997
- poster presentation: American Pain Society - Oct 1997
- manuscript submission: TBD
Post Herpetic Neuralgia (945-211)
- study completed: July 1997
- post-investigators meeting: Oct 1997 (in conjunction with APS) - manuscript: Dec 1997
- manuscript submission: Jan 1998 - JAMA
pgNbr=2
Emerging Uses - Neuropath
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/gdb00a10
|
|
| |
2.
Utah Medicaid Provider Manual: Division of Health Care Financing
|
Document Date:
|
20010700
|
|
Corporate Author:
|
Division of Health Care Financing
|
|
Search Terms in Context:
|
B. Off-Labei, Experimer:tai and invest.:G Orrc: -Drugs
The Utah Medicaid Program restricts the covered drug products on The epe,; fo,rrr ary to uses approved and
documented by the o-ciaiiy recognized compendia 70BRA `993, sect:or. `927 (c) ( .
,d, 15". 7h e designated
compendia are:
Package insert, FDA approved uses
2. American Hospital Forrnuiary Service Drug in ormat on. (A iFS)
3. American Medical Association Drug Evaluation (AMADE)
4. United States ?harrnacopeia D..:C ...°C...CUSP- ~'
DRUGDEX
©f-label Use
The Drug Utilization Review (DUR) Board may approve an ;unlisted of -iabeied use for a given drug if the off
labeled use meets ALL o the following criteria.
I . Use must be diagnosis specific as defined by an 1CD-9 code (s).
2. Off-labeled use must be supported by one major Multi-site study or three smaller studies published in JAMA,
NEJM, aneet or pee- review Spec:aity .med:ca::curna s such as ..C"':a. of vardi^'^CV. A7t c.es ,:rut:- ve
been published within `ve years.
3. Off-labeled use must ha
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/lqa00a10
|
|
| |
3.
Comparative Features of Epilepsy in the Young and Old
|
Document Date:
|
00000000
|
|
Search Terms in Context:
|
Comparative Features of Epilepsy
A in the Young and Old
i
No. of seizure. types
Seizure types
Seizure frequency
Postictal state
Potential for injury
Etiology
Rowan
Young
Many
Multiple
(Frequently GTC)
Often high
Relatively brief
Relatively low
Many
Old
Few
3
(Frequently CPS)
Low
Relatively
prolonged
Relatively high
Few
W L 15777
pgNbr=1
-Ti
M
rn
Comparative Features of Epilepsy
rum in the Young and Old (cont'd)
I
Response to AEDs
Young
Variable
(poor to excellent)
Old
Usually good
(incomplete data)
Often poor
(incomplete data)
Lower
Lower
Tolerance to AEDs Variable
(usually good)
Required doses of AEDs Higher
Speed of AED titration Higher'
Rowan
pgNbr=2
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/qma00a10
|
|
| |
4.
Neurontin Development Team
|
Document Date:
|
00000000
|
|
Search Terms in Context:
|
NEURONTIN
DEVELOPMENT
TEAM
Process Patent: SR3
US: July 2009
EC: June 2011
Lactam - free patent - U.S. only - 1995 issue -
purified form with: <0.5% of lactam
<20 ppm of chloride
USP - strong protection in the US?
Process patent: stabilized preparation of Neurontin
Protection against use of specific excipients - EC only
pgNbr=1
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/sib00a10
|
|
| |
5.
Conference Call Outline
|
Document Date:
|
00000000
|
|
Search Terms in Context:
|
0
Conference Call Outline
Introduction
name, specialty, location
Purpose of call - to answer growing number of questions
regarding oilabel use of Neurontin in bi-polar patients
Statement regarding the approved indication of Neurontin - adjunctive
therapy for partial seizures with or without secondary generabationt
Background
How you became familiar with AED's in psychiatric
patients
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/toa00a10
|
|
| |
6.
Medicaid/QUEST Guidelines for Medication Management of Chronic Non-Cancer Pain: Overall Guidelines
|
Document Date:
|
00000000
|
|
Search Terms in Context:
|
Medicaid) VEST Guidelines* for Medication Mana ement of
Chronic Non-Cancer
OVERALL GUIDELINES
APPENDIX II: MEDICATION SELECTION FOR OUTPATIENT TREATMENT OF CHRONIC NON-
CANCER PAIN
1. Simple analgesics (NSAIDS, acetaminophen)
- Principles of prescribing: c basis / Not more that 2-4 gms per day i s NSAhe from chronict class
/ If failure with one NSAID, try / Monitor for potential of liver, renal, GI toxicities
Worst candidates:
- Best candidates:
/ Mild to moderate pain in the acute/sub-acute History of GI bleed
/ Inflammatory component to pain syndrome Severe pain if prescribed alone
/ As co- analgesics
2. Opioids
- principles for prescribing:
/ Single prescribing physician with single pharmacy when possible
Start with lowest possible dose - but be willing to titrate upwards if needed
/ Use long acting opioids for maintenance of continuous pain (e.g. controlled release
oxycodone; methadone, if closely monitored)
/ Minimize use of short acting opioids for break through pain (e.g
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/uya00a10
|
|
| |
7.
Fee-For-Service Provider Manual Authorization/IHS Referral Chapter: 6
|
Document Date:
|
19990700
|
|
Corporate Author:
|
AHCCCS
|
|
Search Terms in Context:
|
Fee-For-Service Provider Manual July, 1999
A
acs Authorization/HIS Referral
Chapter: 6
Page: 6 - 7
PRIOR AUTHORIZATION OF ACUTE SERVICES (CONT.)
Non-emergency transportation
/ Non-emergency transportation provided by ground ambulance, air ambulance, and non-
ambulance vehicles require PA.
/ Only codes for the base rate and mileage will be prior authorized.
/ This service is not covered for ESP recipients.
H Nursing facilities
/ PA must be obtained before admission of an acute care recipient unless the recipient becomes
retroactively eligible for AHCCCS.
® No PA is required during the retro period, but the stay is subject to medical review.
/ Initial authorization will not exceed the recipient's anticipated fee-for-service enrollment period
or a medically necessary length of stay, whichever is shorter.
/ Reauthorization for continued stay is subject to concurrent utilization review by AHCCCS or its
designee.
/ AHCCCS will allow up to 90 days of nursing facility care in a contract year (10
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/xxa00a10
|
|
| |
8.
Neurontin Neu Starts Initiative
|
Document Date:
|
00000000
|
|
Search Terms in Context:
|
NEURONTIN Neu Starts initiative °:
Objectives
- Provide Territory Managers with a tool to introduce
new monotherapy indication
Accelerate physician prescribing of Neurontin for
monotherapy
-- Generate greater TMOT spillover into 1998 via
new patient starts for epilepsy
pgNbr=1
NEURONTIN NeuStailslniUaUve
Overview
-- Territory Managers provided samples or stock
packages to "incentivize" physician to Rx
Neurontin for monotherapy
-- Physician should have a minimal yet active role in
the process (e.g., dose titration chart) to increase
credibility of the initiative
Not just a seeding or sampling program
.- TMs should focus physician on the "ideal"
Neurontin monotherapy patients
pgNbr=2
NEURONflN Nea Ms Iaibsative
Key Factors
-- Physician target list: total number, decile,
specialty, average number/rep, Rxing trends
-- Cost of Goods:
standard cost of goods (300mg 100's) : $5.70
Quantity of "starter kits"/physician
Supplemental materials: e.g, patient education,
physician materials
- . Target date/
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/yhb00a10
|
|
| |
9.
Efficacy of Conjugated Equine Estrogens and Trimegestone on Bone Mineral Density in Postmenopausal Women
|
Document Date:
|
20021108
|
|
Corporate Author:
|
OCC North America
|
|
Page Count:
|
6
|
|
Search Terms in Context:
|
sources:
• CSR-41402
• Biomedical literature
Outline
I. Abstract (per journal guidelines)
II. Introduction
A. The loss of ovarian function and the subsequent depletion of estrogen in
postmenopausal women can lead to several physiologic changes; osteoporosis is a long-term consequence of estrogen depletion
B. It has been estimated that 30 million women
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/srb37b10
|
|
| |
10.
Arterial Versus Venous Effects of Estrogen Manuscript Outline, Target Journal: American Journal of Medicine
|
Document Date:
|
00000000
|
|
Page Count:
|
7
|
|
Search Terms in Context:
|
1
Arterial Versus Venous Effects of Estrogen Manuscript Outline
Target Journal: American Journal of Medicine
Abstract
I. Introduction
1 Coronary heart disease (CHD) is a leading cause of mortality among postmenopausal women (American Heart Association, 2001).
2 Observational and prospective studies suggest there is a 30%-40% decrease in the relative risk of a primary cardiovascular
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/rcc37b10
|
|
| |
|
Prev
Next
|
